These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 20847637)

  • 21. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation study of the Alzheimer's Disease Assessment Scale-Cognitive Subscale for people with mild cognitive impairment and Alzheimer's disease in Chinese communities.
    Yang H; Cheng Z; Li Z; Jiang Y; Zhao J; Wu Y; Gu S; Xu H
    Int J Geriatr Psychiatry; 2019 Nov; 34(11):1658-1666. PubMed ID: 31347192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.
    Koppara A; Wolfsgruber S; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Jessen F; Kornhuber J; Wagner M
    J Alzheimers Dis; 2016; 49(2):547-60. PubMed ID: 26484902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the utility of everyday memory test and the Alzheimer's Disease Assessment Scale-Cognitive part for evaluation of mild cognitive impairment and very mild Alzheimer's disease.
    Adachi H; Shinagawa S; Komori K; Toyota Y; Mori T; Matsumoto T; Sonobe N; Kashibayashi T; Ishikawa T; Fukuhara R; Ikeda M
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):148-53. PubMed ID: 23581865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
    Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
    Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative.
    Song X; Mitnitski A; Zhang N; Chen W; Rockwood K;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):71-8. PubMed ID: 23123510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
    Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
    Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study.
    Harrison JE; Rentz DM; Brashear HR; Arrighi HM; Ropacki MT; Liu E
    J Prev Alzheimers Dis; 2018; 5(4):236-244. PubMed ID: 30298182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Semi-supervised multimodal relevance vector regression improves cognitive performance estimation from imaging and biological biomarkers.
    Cheng B; Zhang D; Chen S; Kaufer DI; Shen D;
    Neuroinformatics; 2013 Jul; 11(3):339-53. PubMed ID: 23504659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Neuropsychological Correlates of Brain Perfusion and Gray Matter Volume in Alzheimer's Disease.
    Tai H; Hirano S; Sakurai T; Nakano Y; Ishikawa A; Kojima K; Li H; Shimada H; Kashiwado K; Mukai H; Horikoshi T; Sugiyama A; Uno T; Kuwabara S
    J Alzheimers Dis; 2020; 78(4):1639-1652. PubMed ID: 33185599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diagnostic value and functional correlations of the ADAS-Cog scale in Alzheimer's disease: data on NORMACODEM project].
    Monllau A; Pena-Casanova J; Blesa R; Aguilar M; Bohm P; Sol JM; Hernandez G
    Neurologia; 2007 Oct; 22(8):493-501. PubMed ID: 17602338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment.
    Schmand B; Eikelenboom P; van Gool WA;
    J Alzheimers Dis; 2012; 29(3):641-8. PubMed ID: 22297644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials.
    Chang TS; Teng E; Elashoff D; Grill JD;
    Alzheimer Dis Assoc Disord; 2017; 31(1):19-26. PubMed ID: 27196535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population.
    Hannesdóttir K; Snaedal J
    Nord J Psychiatry; 2002; 56(3):201-6. PubMed ID: 12079572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.
    Landau SM; Harvey D; Madison CM; Koeppe RA; Reiman EM; Foster NL; Weiner MW; Jagust WJ;
    Neurobiol Aging; 2011 Jul; 32(7):1207-18. PubMed ID: 19660834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
    Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
    J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?
    Balsis S; Benge JF; Lowe DA; Geraci L; Doody RS
    Clin Neuropsychol; 2015; 29(7):1002-9. PubMed ID: 26617181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease.
    Velayudhan L; Proitsi P; Westman E; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Spenger C; Hodges A; Powell J; Lovestone S; Simmons A;
    J Alzheimers Dis; 2013; 33(3):755-66. PubMed ID: 23047370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting conversion of patients with Mild Cognitive Impairment to Alzheimer's disease using bedside cognitive assessments.
    Clarke A; Ashe C; Jenkinson J; Rowe O; A D N I ; Hyland P; Commins S
    J Clin Exp Neuropsychol; 2022 Dec; 44(10):703-712. PubMed ID: 36803664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.